Loading
Cancer, Hypoxia, and Metabolism / Clusterin in Disease Pathology / Ferroptosis and Cancer Prognosis · Journal article
Molecular Cancer · July 23, 2026
Encouraging direction, but not yet definitive.
This preclinical study identifies a mechanistic link between mutant p53 and ferroptosis resistance in pancreatic cancer, mediated by metabolic plasticity and glycolytic reprogramming. Pharmacological reactivation of wild-type p53 combined with ferroptosis inducers overcomes this resistance in cell and orthotopic mouse models, suggesting a potential therapeutic strategy that requires clinical evaluation.
Preclinical mechanistic study combining isogenic cell models, transcriptomics, metabolic flux analysis, and orthotopic murine xenografts. Pancreatic ductal adenocarcinoma cell lines engineered with TP53 modifications; C57BL/6 or immunocompromised mice bearing orthotopic PDAC xenografts.. Intervention: Ferroptosis inducers; pharmacological reactivation of wild-type p53 in combination with ferroptosis inducers; glucose supplementation; glycolytic inhibition.. Compared with: TP53-knockout cells versus mutant TP53-expressing cells; untreated controls implied but not explicitly described..
Deletion of mutant TP53 sensitized pancreatic cancer cells to ferroptosis with increased oxidative stress, lipid peroxidation and mitochondrial dysfunction. Mutant TP53 expression preserved mitochondrial integrity and sustained bioenergetic flexibility under ferroptotic stress. Glucose supplementation enhanced survival under ferroptotic conditions in mutant TP53-expressing cells, but glycolytic inhibition impaired it.
In vivo efficacy described qualitatively; no survival data, tumor growth curves, or toxicity metrics reported in abstract. Pharmacological reactivation of wild-type p53 significantly increased ferroptotic cell death both in vitro and in vivo in orthotopic murine models.
These findings identify metabolic reprogramming as a mechanism of ferroptosis resistance in TP53-mutant PDAC and suggest that combining p53 reactivation with ferroptosis inducers may overcome this resistance. The work provides preclinical rationale for clinical development of this combination, though translation to patients requires human trials.
Mechanistic study in cell and animal models demonstrating mutant p53-driven ferroptosis resistance and a potential combination therapeutic approach, but lacks clinical trial data and hard patient outcomes.
As stated by the source record.
These findings identify metabolic reprogramming as a mechanism of ferroptosis resistance in TP53-mutant PDAC and suggest that combining p53 reactivation with ferroptosis inducers may overcome this resistance. The work provides preclinical rationale for clinical development of this combination, though translation to patients requires human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by late diagnosis, rapid progression, and resistance to conventional therapies. Mutations in the tumor suppressor gene TP53 are prevalent in this cancer and have been associated with gain-of-function activities that promote tumor survival. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, represents a potential therapeutic vulnerability. However, the influence of mutant p53 on ferroptosis susceptibility remains poorly understood. We employed isogenic pancreatic cancer cell models, including CRISPR-Cas9-mediated TP53 Knockout ( TP53 -KO) and transient overexpression of common mutant TP53 variants, to examine ferroptosis sensitivity. Cell viability, reactive oxygen species accumulation, lipid peroxidation, mitochondrial integrity, and metabolic profiling were assessed following treatment with ferroptosis inducers. Transcriptional changes were analysed by RNA sequencing, and functional contributions of glycolysis and mitochondrial respiration were evaluated using metabolic flux assays. Pharmacological reactivation of wild-type p53 was tested in combination with ferroptosis inducers in vitro and in orthotopic murine models. Deletion of mutant TP53 sensitized pancreatic cancer cells to ferroptosis, accompanied by increased oxidative stress, lipid peroxidation and mitochondrial dysfunction. Mutant TP53 expression preserved mitochondrial integrity and sustained bioenergetic flexibility under ferroptotic stress. Transcriptomic analyses revealed a multi-layered adaptive program, including upregulation of antioxidant and metabolic genes, and activation of PI3K–AKT signaling, which is associated to a selective glycolytic shift to maintain ATP levels. Functional modulation confirmed that glucose supplementation enhanced, whereas glycolytic inhibition impaired, survival under ferroptotic conditions in mutant TP53 -expressing cells, but not in TP53- KO cells. Pharmacological reactivation of wild-type p53 disrupted this adaptive network, abrogating glycolytic reprogramming and significantly increasing ferroptotic cell death both in vitro and in vivo. Mutant p53 orchestrates transcriptional and metabolic plasticity that confers ferroptosis resistance in pancreatic cancer. Reactivating wild-type p53 in combination with ferroptosis induction overcomes this resistance, highlighting a therapeutically actionable vulnerability and supporting the development of combinatorial strategies for this aggressive malignancy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.